NASDAQ:GLYC GlycoMimetics (GLYC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About GlycoMimetics Stock (NASDAQ:GLYC) 30 days 90 days 365 days Advanced Chart Get GlycoMimetics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.16▼$27.4752-Week Range N/AVolume1.05 million shsAverage Volume63,887 shsMarket Capitalization$10.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company OverviewGlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Read More… GlycoMimetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreGLYC MarketRank™: GlycoMimetics scored higher than 36% of companies evaluated by MarketBeat, and ranked 781st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for GlycoMimetics.Read more about GlycoMimetics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for GlycoMimetics are expected to remain at ($0.08) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about GlycoMimetics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.90% of the float of GlycoMimetics has been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlycoMimetics has recently increased by 1.79%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.55 Percentage of Shares Shorted2.90% of the float of GlycoMimetics has been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlycoMimetics has recently increased by 1.79%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.93 News SentimentGlycoMimetics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for GlycoMimetics this week, compared to 1 article on an average week.Search Interest1 people have searched for GLYC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GlycoMimetics' insider trading history. Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLYC Stock News HeadlinesCrescent Biopharma Inc.June 24, 2025 | barrons.comLifeSci Capital Initiates Coverage of GlycoMimetics (CBIO) with Outperform RecommendationJune 20, 2025 | msn.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer. | Timothy Sykes (Ad)GlycoMimetics (NASDAQ:GLYC) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?June 20, 2025 | americanbankingnews.comGlycoMimetics trading halted, news pendingJune 14, 2025 | msn.comGlycoMimetics announces 1-for-100 reverse stock splitJune 7, 2025 | investing.comGlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related ProposalsJune 5, 2025 | businesswire.comCrescent Biopharma to Present at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comSee More Headlines GLYC Stock Analysis - Frequently Asked Questions How were GlycoMimetics' earnings last quarter? GlycoMimetics, Inc. (NASDAQ:GLYC) released its quarterly earnings data on Wednesday, May, 14th. The biotechnology company reported ($4.00) EPS for the quarter, beating the consensus estimate of ($5.00) by $1.00. When did GlycoMimetics' stock split? Shares of GlycoMimetics reverse split on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are GlycoMimetics' major shareholders? GlycoMimetics' top institutional shareholders include Wellington Management Group LLP (2.12%) and Jefferies Financial Group Inc. (0.91%). Insiders that own company stock include Public Equities LP Invus, Edwin Rock, Bruce S Johnson and Brian M Hahn. View institutional ownership trends. How do I buy shares of GlycoMimetics? Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Bristol Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA). Company Calendar Last Earnings5/14/2025Today6/28/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLYC CIK1253689 Webwww.glycomimetics.com Phone(240) 243-1201Fax301-738-2137Employees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.88 million Net MarginsN/A Pretax Margin-397,340.00% Return on Equity-230.74% Return on Assets-177.39% Debt Debt-to-Equity RatioN/A Current Ratio1.92 Quick Ratio1.92 Sales & Book Value Annual Sales$10 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / BookN/AMiscellaneous Outstanding Shares64,532,000Free Float58,901,000Market Cap$10.00 million OptionableOptionable Beta1.62 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:GLYC) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.